CAR T-associated toxicities
| Acute phase (Days 0-30) . | Late phase (After first 30 days) . |
|---|---|
| • CRS • ICANS • Cytopenias ○ MAS or HLH is a very rare and severe form ○ DIC • B-cell aplasia and hypogammaglobulinemia • Life threatening if not managed by expert multidisciplinary team • Tumor lysis is rare and likely varies by disease and disease burden | • Persistent cytopenias • B-cell aplasia and hypogammaglobulinemia ○ IVIG replacement? • T-cell deficiency ○ PJP and VZV prophylaxis, other? • Infection prophylaxis • Residual effects of acute toxicity • Delayed CRS and neurotoxicity is rare but can occur • Impairment to QOL—fatigue, memory issues, not yet well described |
| Acute phase (Days 0-30) . | Late phase (After first 30 days) . |
|---|---|
| • CRS • ICANS • Cytopenias ○ MAS or HLH is a very rare and severe form ○ DIC • B-cell aplasia and hypogammaglobulinemia • Life threatening if not managed by expert multidisciplinary team • Tumor lysis is rare and likely varies by disease and disease burden | • Persistent cytopenias • B-cell aplasia and hypogammaglobulinemia ○ IVIG replacement? • T-cell deficiency ○ PJP and VZV prophylaxis, other? • Infection prophylaxis • Residual effects of acute toxicity • Delayed CRS and neurotoxicity is rare but can occur • Impairment to QOL—fatigue, memory issues, not yet well described |
CRS, cytokine release syndrome; DIC, disseminated intravascular coagulopathy; HLH, hemophagocytic lymphohistiocytosis; ICANS, immune effector cell–associated neurotoxicity syndrome; IVIG, intravenous immunoglobulin; MAS, macrophage activation syndrome; PJP, pneumocystis jirovecii pneumonia; QOL, quality of life; VZV, varicella zoster virus.